시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 오가노이드 시장 보고서(2025년)
Organoids Global Market Report 2025
상품코드 : 1824301
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 오가노이드 시장 규모는 향후 수년간 비약적인 성장이 예상됩니다. 2029년까지 CAGR 22.2%로 확대되어 107억 6,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 만성질환의 유병률 증가, 유전자 편집기술의 진보, 줄기세포 연구 증가, 공동 연구와 파트너십, 임상 번역의 노력에 기인하는 것으로 예측됩니다. 예측 기간의 주요 동향으로는 재생 의료에의 응용, in vivo 이미징 기술, 다장기 시스템에 대한 공동 연구, 윤리적 및 법적 배려, 상업화, 시장 확대 등을 들 수 있습니다.

향후 5년간의 성장률 22.2%라는 예측은 지난 예측으로부터 0.1% 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세의 상승은 스웨덴과 일본에서 조달하는 3D 바이오프린팅 시스템이나 줄기세포 배양 배지 성분의 비용을 끌어올려, 의약품 개발 비용을 악화시키고, 맞춤형 의료의 돌파구를 늦추는 것으로, 미국의 생물 의료 연구에 부담을 줄 가능성이 높습니다. 이 영향은 또한 상호관세와 무역 긴장 증가와 제한으로 인한 세계 경제와 무역에 대한 악영향에 의해 더욱 넓어지는 것으로 예측됩니다.

만성 질환과 감염의 이환율과 유병률 증가는 향후 오가노이드 시장의 성장을 이끌 것으로 예측됩니다. 만성 질환이란 1년 이상 지속되고 지속적인 의료가 필요한 상태를 말합니다. 오가노이드는 다양한 만성 질환과 그 치료법의 조사에 이용되고 있어 병원체의 생물학적 성질이나 약제의 스크리닝에 대해 즉각적으로 신뢰성 높은 지견을 얻을 수 있기 때문입니다. 따라서 이러한 질병의 발생률과 유병률이 증가하면 유기농 시장이 강화됩니다. 예를 들어, 2024년 6월 영국의 공적 의료 제도인 National Health Service는 GP에 등록된 개인이 2023년에 비당뇨병성 고혈당, 또는 당뇨병 위험군으로 진단된 것은 361만 5,330명으로 2022년의 306만 5,825명에서 증가했습니다. 따라서 만성질환의 유병률 증가는 오가노이드 시장을 촉진할 것으로 예측됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

Organoids, intricate three-dimensional tissue cultures derived from stem cells, serve as invaluable assets in tailored regenerative medicine, gene repair, and transplantation therapy.

These organoids come in various forms such as hepatic, colorectal, and intestinal, among others. Hepatic organoids, for instance, represent fully functional in vitro models of the liver. They play a pivotal role in addressing an array of research queries related to hepatic development, regeneration, and disease modeling. These groundbreaking tools harness different sources, including pluripotent stem cells and organ-specific adult stem cells. They find application across developmental biology, infectious disease pathology, regenerative medicine, drug efficacy and toxicity testing, as well as drug discovery and personalized medicine. Their adoption spans a wide spectrum, encompassing hospitals, diagnostic centers, biotechnology and pharmaceutical companies, and other industries seeking to leverage their immense potential for advancements in healthcare and research.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The organoids market research report is one of a series of new reports from The Business Research Company that provides organoids market statistics, including organoids industry global market size, regional shares, competitors with a organoids market share, detailed organoids market segments, market trends, and opportunities, and any further data you may need to thrive in the organoids industry. This organoids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The organoids market size has grown exponentially in recent years. It will grow from $3.98 billion in 2024 to $4.82 billion in 2025 at a compound annual growth rate (CAGR) of 21.0%. The growth in the historic period can be attributed to biomedical research advances, drug discovery and development needs, disease modeling requirements, personalized medicine trends, and regulatory support.

The organoids market size is expected to see exponential growth in the next few years. It will grow to $10.76 billion in 2029 at a compound annual growth rate (CAGR) of 22.2%. The growth in the forecast period can be attributed to the increased prevalence of chronic diseases, advancements in genome editing techniques, rise in stem cell research, collaborations and partnerships, and clinical translation efforts. Major trends in the forecast period include application in regenerative medicine, in vivo imaging techniques, collaborations for multi-organoid systems, ethical and legal considerations, commercialization and market expansion.

The forecast of 22.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. biomedical research by driving up the cost of 3D bioprinting systems and stem cell culture media components sourced from Sweden and Japan, exacerbating drug development costs and delaying personalized medicine breakthroughs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

An increase in the incidence and prevalence of chronic and infectious diseases is expected to drive the growth of the organoid market in the future. Chronic diseases are conditions that persist for over a year and require continuous medical care. Organoids are utilized to investigate various chronic diseases and their treatments, as they provide immediate and reliable insights into pathogen biology and drug screening. Thus, the rise in the incidence and prevalence of these diseases will bolster the organoid market. For example, in June 2024, the National Health Service, a publicly funded healthcare system in the UK, reported that 3,615,330 individuals registered with a GP were diagnosed with non-diabetic hyperglycemia, or pre-diabetes, in 2023, up from 3,065,825 in 2022, representing an increase of nearly 18%. Therefore, the growing prevalence of chronic diseases is expected to propel the organoid market.

The escalating number of clinical trials aimed at drug development is set to fuel the expansion of the organoid market. These trials, totaling 452,604 globally as of May 17, 2023, registered on ClinicalTrials.gov-an increase from over 365,000 trials in early 2021, underscore the growing utilization of organoids. Leveraged in modeling diseases and refining personalized medicine, organoids play a pivotal role in advancing scientific understanding and improving patient care, solidifying their contribution to market growth.

Technological advancements stand as a prominent trend shaping the organoid market. Companies within this sector continuously introduce cutting-edge technologies to fortify their market positions. Notably, in March 2023, MIMETAS unveiled the OrganoReady product line featuring a novel adult stem cell-derived tubular organoid, harnessing innovative technology for mechanistic toxicology and drug-induced organ injury assessments. Developed on the patented microfluidic platform, OrganoPlate, these perfused 3D structures demonstrate the industry's commitment to pioneering advancements in organoid technologies.

Market leaders prioritize the development of pioneering platforms such as organoid panel screening, driving progress in preclinical oncology drug discovery. For example, in November 2023, Crown Bioscience launched OrganoidXplore, a revolutionary large-scale organoid panel screening platform. Utilizing their AR organoid technology, this platform streamlines preclinical drug discovery by offering reliable drug response comparisons that faithfully replicate original tumors' genomic, morphological, and pathophysiological characteristics. With enhanced performance and cost-effectiveness, OrganoidXplore signals a significant stride in accelerating oncology drug discovery.

In December 2022, Molecular Devices LLC, a UK-based research and development company, acquired Cellesce Ltd. for an undisclosed amount. The acquisition will provide Molecular Devices LLC with Cellesce Ltd human-derived cell or organoid lines and strengthen the company's position as a 3D biology solutions innovator. Cellesce Ltd is a UK-based company with expertise in cell expansion focused on organoids.

Major companies operating in the organoids market include Cellesce Ltd., STEMCELL Technologies, HUB Organoids, DefiniGEN, 3Dnamics Inc., OcellO B.V., Organoid Therapeutics, PeproTech Inc., QGel SA, Corning Incorporated, Thermo Fisher Scientific, Trevigen Inc., Path BioAnalytics, R&D Systems, Merck KGaA, 3D BioMatrix Inc., 3D Biotek LLC, AMS Biotechnology (Europe) Limited, Greiner Bio-One, 3-D Matrix, InSphero AG, Synthego Corporation, Axol Bioscience Ltd., TissUse GmbH, CytoSMART Technologies BV, EMD Millipore Corporation, Epithelix Sarl

North America was the largest region in the organoids market in 2024. Asia-pacific is expected to be the fastest-growing region in the global organoids market size forecast period. The regions covered in the organoids market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the organoids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The organoids market consists of sales of epithelial organoid, embryonic organoid, and cerebral organoid. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Organoids Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on organoids market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for organoids ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The organoids market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Organoids Market Characteristics

3. Organoids Market Trends And Strategies

4. Organoids Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Organoids Growth Analysis And Strategic Analysis Framework

6. Organoids Market Segmentation

7. Organoids Market Regional And Country Analysis

8. Asia-Pacific Organoids Market

9. China Organoids Market

10. India Organoids Market

11. Japan Organoids Market

12. Australia Organoids Market

13. Indonesia Organoids Market

14. South Korea Organoids Market

15. Western Europe Organoids Market

16. UK Organoids Market

17. Germany Organoids Market

18. France Organoids Market

19. Italy Organoids Market

20. Spain Organoids Market

21. Eastern Europe Organoids Market

22. Russia Organoids Market

23. North America Organoids Market

24. USA Organoids Market

25. Canada Organoids Market

26. South America Organoids Market

27. Brazil Organoids Market

28. Middle East Organoids Market

29. Africa Organoids Market

30. Organoids Market Competitive Landscape And Company Profiles

31. Organoids Market Other Major And Innovative Companies

32. Global Organoids Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Organoids Market

34. Recent Developments In The Organoids Market

35. Organoids Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기